Table 1. Binding affinities of human IGF2, Leu19-IGF2, human insulin and human IGF1 for D11, IR-A and IGF1R (details are provided in methods).
| Analog | D11 of IGF2R | IGF1R | IR-A | |||
|---|---|---|---|---|---|---|
| Kd ± S.D. [nM] (n) | Relative binding affinity [%] | Kd ± S.D. [nM] (n) | Relative binding affinity [%] | Kd ± S.D. [nM] (n) | Relative binding affinity [%] | |
| IGF2 | 1.0 ± 0.7 (12) | 100 | 1.6 ± 0.3 (4) | 12.1 | 2.6 ± 0.4 (3) | 10.4 |
| Leu19-IGF2 | 0.28 ± 0.1 (6) | 357 | 1.1 ± 0.1 (2) | 16.7 | 7.3 ± 0.8 (3) | 3.7 |
| human insulin | n.d. | - | 290* | 0.8* | 0.27 ± 0.06 (4) | 100 |
| IGF1 | no binding (2) | - | 0.19 ± 0.08 (5) | 100 | 24* | 0.9* |
The Kd values and relative binding affinities were calculated from at least three independent measurements. (n) is number of replicates. Relative binding affinity is defined as Kd of native hormone/Kd of analog x 100.
*Data from Ref. [44].